Certolizumab pegol: a new biologic targeting rheumatoid arthritis.
about
Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseasesA window on disease pathogenesis and potential therapeutic strategies: molecular imaging for arthritis.Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID studyMethotrexate: an old new drug in autoimmune disease.
P2860
Certolizumab pegol: a new biologic targeting rheumatoid arthritis.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Certolizumab pegol: a new biologic targeting rheumatoid arthritis.
@en
Certolizumab pegol: a new biologic targeting rheumatoid arthritis.
@nl
type
label
Certolizumab pegol: a new biologic targeting rheumatoid arthritis.
@en
Certolizumab pegol: a new biologic targeting rheumatoid arthritis.
@nl
prefLabel
Certolizumab pegol: a new biologic targeting rheumatoid arthritis.
@en
Certolizumab pegol: a new biologic targeting rheumatoid arthritis.
@nl
P2860
P356
P1476
Certolizumab pegol: a new biologic targeting rheumatoid arthritis.
@en
P2093
Aarat M Patel
Larry W Moreland
P2860
P304
P356
10.1586/ECI.10.69
P577
2010-11-01T00:00:00Z